Clinical Manual for Management of the HIV-Infected ... - myCME.com

More documents

Recommendations

Info

Patient Education ♦ ♦ ♦ ♦ ♦ Recommend scrupulous handwashing for the patient and all contacts, especially household members and sexual partners. Explain that effective ART is the best treatment for alleviating symptoms and helping the immune system eradicate the parasite. Advise the patient to increase fluid intake (not alcohol), and avoid foods that aggravate diarrhea. Educate the patient about healthful food choices that increase calories and nutrition. Provide supportive counseling; discuss how to manage symptoms and the isolation that may accompany chronic diarrhea. References ♦ ♦ ♦ Section 6—Disease-Specific Treatment | 6–23 Bartlett JG, Gallant JE. 2005-2006 Medical Management of HIV Infection. Baltimore: Johns Hopkins University Division of Infectious Diseases; 2005. Available online at hopkins-aids.edu/mmhiv/ order.html. Centers for Disease Control and Prevention, National Institutes of Health, HIV Medicine Association/Infectious Diseases Society of America. Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents. MMWR Recomm Rep. 2004 Dec 17; 53(RR15);1-112. Available online at aidsinfo.nih.gov/Guidelines/GuidelineDetail. aspx?GuidelineID=14. Accessed June 1, 2006. Leder K, Weller PF. Cryptosporidiosis [online resource]. Waltham, MA: Up to Date; April 2005. Available online at www.uptodate.com/index.asp. [Fee required.]
Page 1 and 2:
Clinical Manual for Management of t
Page 3 and 4:
Table of Contents Clinical Manual f
Page 5 and 6:
Clinical Manual for Management of t
Page 7 and 8:
Preface—About this Manual | Clini
Page 9:
Previous Editions Atlanta Contribut
Page 12 and 13:
♦ ♦ ♦ ♦ ♦ | Clinical Manu
Page 14 and 15:
1-2 | Clinical Manual for Managemen
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 23 and 24:
Initial Physical Examination Backgr
Page 25 and 26:
Genitals/Rectum • Inspect the gen
Page 27 and 28:
Initial and Interim Laboratory and
Page 29 and 30:
Section 1—Testing and Assessment
Page 31:
Patient Education ♦ ♦ ♦ ♦ D
Page 34 and 35:
1-22 | Clinical Manual for Manageme
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 51 and 52:
Section 2—Health Maintenance and
Page 53:
References ♦ ♦ ♦ ♦ ♦ ♦
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 67 and 68:
Occupational Postexposure Prophylax
Page 69 and 70:
P: Plan Laboratory Testing Provide
Page 71 and 72:
For hepatitis C, no recommended pro
Page 73 and 74:
Page 75 and 76:
as hepatitis C or another sexually
Page 77 and 78:
for treatment is appropriate, and b
Page 79 and 80:
Page 81 and 82:
contact with the patient. Patients
Page 83 and 84:
tablet daily of trimethoprim-sulfam
Page 85 and 86:
Opportunistic Infection Prophylaxis
Page 87 and 88:
Discontinuing Primary Prophylaxis P
Page 89 and 90:
Latent Tuberculosis Background Late
Page 91 and 92:
INH may cause liver toxicity and it
Page 93:
Patient Education ♦ ♦ ♦ ♦
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 117 and 118:
Reducing Maternal-Infant HIV Transm
Page 119 and 120:
Some states require written informe
Page 121 and 122:
contraindicated during pregnancy be
Page 123 and 124:
Section 3—Antiretroviral Therapy
Page 125 and 126:
Nelfinavir (Viracept) Adequate drug
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133:
♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 165 and 166:
Section 4—Complications of Antire
Page 167 and 168:
♦ ♦ ♦ Toronto General Hospita
Page 169 and 170:
Adverse Reactions to HIV Medication
Page 171 and 172:
♦ ♦ ♦ ♦ ♦ Vital signs: No
Page 173 and 174:
egimen, symptoms of fatigue could i
Page 175 and 176:
Recreational Drugs and Antiretrovir
Page 177 and 178:
Section 4—Complications of Antire
Page 179 and 180:
LSD, Mescaline, Psilocin, and Methy
Page 181 and 182:
Immune Reconstitution Syndrome Back
Page 183 and 184:
A: Assessment In the appropriate cl
Page 185 and 186:
♦ ♦ ♦ ♦ ♦ Navas E, Martin
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 202 and 203:
Eye Problems Background The immunos
Page 204:
of
Page 207 and 208: 5-22 | Clinical Manual for Manageme
Page 210 and 211: Fever Background Although fever may
Page 212 and 213: Headache Background Headache may ha
Page 214 and 215: Lymphadenopathy Background Lymphade
Page 216: Treatment Treatment will depend on
Page 222 and 223: Neurologic Symptoms Background The
Page 224 and 225: ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦
Page 226 and 227: Pulmonary Symptoms Background Short
Page 228: Treatment Once the diagnosis is mad
Page 235 and 236: 6-2 | Clinical Manual for Managemen
Page 238 and 239: Candidiasis, Oral and Esophageal Ba
Page 240: Maintenance therapy Use caution whe
Page 246 and 247: Cervical Dysplasia Background Cervi
Page 248: Patient Education ♦ ♦ ♦ ♦ P
Page 254 and 255: Cryptosporidiosis Background Crypto
Page 258 and 259: Cytomegalovirus Disease Background
Page 260 and 261: CMV retinitis Treatment consists of
Page 262 and 263: Dermatologic Staphylococcal Infecti
Page 264: Known or suspected MSSA SSTI Treat
Page 282 and 283: Herpes Zoster/Shingles Background S
Page 284 and 285: Histoplasmosis Background Histoplas
Page 286: Patient Education ♦ ♦ ♦ ♦ H
Page 308 and 309:
Section 6—Disease-Specific Treatm
Page 310 and 311:
Table 1. World Health Organization
Page 312:
Table 3. Monitoring for Toxicity Si
Page 315 and 316:
Page 318 and 319:
Pelvic Inflammatory Disease Backgro
Page 320 and 321:
Table 1. Treatment Regimens for Pel
Page 322 and 323:
Pneumocystis Pneumonia Background P
Page 324 and 325:
Table 1. Standard and Alternative P
Page 326 and 327:
Progressive Multifocal Leukoencepha
Page 328 and 329:
Seborrheic Dermatitis Background Se
Page 330 and 331:
Sinusitis Background Sinusitis is d
Page 332 and 333:
Syphilis Background Syphilis is a s
Page 334 and 335:
Treponemal antibody tests (TP-PA [T
Page 336:
Some patients retain reactive (low-
Page 339 and 340:
6-106| Clinical Manual for Manageme
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Pain Syndrome and Peripheral Neurop
Page 359 and 360:
Pharmacologic interventions The fol
Page 361 and 362:
Page 363 and 364:
Palliative Care and HIV Background
Page 365 and 366:
GASTROINTESTINAL Nausea, vomiting
Page 367:
Advance Care Planning Advance care
Page 370 and 371:
Page 373 and 374:
Depression Background Major depress
Page 375 and 376:
of symptoms. The risk of recurrence
Page 377 and 378:
Panic Disorder Background Panic dis
Page 379:
♦ If benzodiazepines are used, th
Page 382 and 383:
Page 384 and 385:
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
Page 392 and 393:
Page 395 and 396:
Sulfa Desensitization Background Tr
Page 397 and 398:
Patient Education Background It has
Page 399 and 400:
Web-Based Resources Background The
show all

Clinical Manual for Management of the HIV-Infected ... - myCME.com

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?